A combination of mRNA and a new lipid nanoparticle could help heal damaged lungs, according to new research from the Perelman School of Medicine. Viruses, physical trauma, or other problems can have serious impact on lungs, and when the damage is in the lower regions, traditional treatments, like inhaled medication, might not work. The study, published in Nature Communications, provides a proof of concept for an injectable therapy.
“The lungs are hard-to-treat organs because both permanent and temporary damage often happen in the deeper regions where medication does not easily reach,” says study author Elena Atochina-Vasserman, research assistant professor of Infectious Diseases at Penn and scientist at the Penn Institute for RNA Innovation. “Even drugs delivered intravenously are spread without specificity. That makes a targeted approach like ours especially valuable.”
Lung damage can result from a variety of causes ranging from physical accidents that cause inflammation of the lungs to respiratory viruses like COVID, flu, and RSV. Viruses alone can usher in an inflammatory response setting off a buildup of fluid in the airways, excess mucus, cell death, and damage to the lining of the lungs. Whether acute or chronic, weakened lungs can be life threatening.
The lifesaving mRNA COVID vaccines used unique lipid nanoparticles as the mRNA delivery system. The method in this study matched up mRNA with just one unique lipid nanoparticle—ionizable amphiphilic Janus dendrimers (IAJDs) which were derived from natural materials and discovered by Virgil Percec, the P. Roy Vagelos Professor in Chemistry in the School of Arts & Sciences. Previous research from Percec, Atochina-Vasserman, and others at Penn found that these IAJDs are organ specific, which made them a good candidate to send mRNA explicitly to the lungs. When it reaches the lung, the mRNA then instructs the immune system to create transforming growth factor beta (TGF-b), a signaling molecule vital for the body to repair tissue.
“This research marks the birth of a new mRNA delivery platform with its own strengths and potential beyond the original mRNA LNPs,” says 2023 Nobel laureate Drew Weissman, a co-author of the study, the Roberts Family Professor in Vaccine Research, and director of the Penn Institute for RNA Innovation. “While using other lipid nanoparticles works great to prevent infectious diseases, in addition to being specific to the lung, this new platform does not have to be stored at such extremely cold temperatures and is even easier to produce.”
Read more at Penn Medicine News.
